| Literature DB >> 31597755 |
Honghai Liu1, Cheng-Hai Zhang2,3, Niyatie Ammanamanchi1, Sangita Suresh2,3, Christopher Lewarchik1, Krithika Rao1, Gerrida M Uys2,3, Lu Han1, Maryline Abrial2,3, Dean Yimlamai4, Balakrishnan Ganapathy1, Christelle Guillermier5, Nathalie Chen1, Mugdha Khaladkar6, Jennifer Spaethling7, James H Eberwine7, Junhyong Kim6, Stuart Walsh2,3, Sangita Choudhury2,3, Kathryn Little1, Kimberly Francis1, Mahesh Sharma8, Melita Viegas9, Abha Bais10, Dennis Kostka10,11,12, Jun Ding13, Ziv Bar-Joseph13, Yijen Wu10,14, Vijay Yechoor15, Mousumi Moulik16, Jennifer Johnson16,17, Jacqueline Weinberg16, Miguel Reyes-Múgica18, Matthew L Steinhauser5, Bernhard Kühn19,20,21.
Abstract
One million patients with congenital heart disease (CHD) live in the United States. They have a lifelong risk of developing heart failure. Current concepts do not sufficiently address mechanisms of heart failure development specifically for these patients. Here, analysis of heart tissue from an infant with tetralogy of Fallot with pulmonary stenosis (ToF/PS) labeled with isotope-tagged thymidine demonstrated that cardiomyocyte cytokinesis failure is increased in this common form of CHD. We used single-cell transcriptional profiling to discover that the underlying mechanism of cytokinesis failure is repression of the cytokinesis gene ECT2, downstream of β-adrenergic receptors (β-ARs). Inactivation of the β-AR genes and administration of the β-blocker propranolol increased cardiomyocyte division in neonatal mice, which increased the number of cardiomyocytes (endowment) and conferred benefit after myocardial infarction in adults. Propranolol enabled the division of ToF/PS cardiomyocytes in vitro. These results suggest that β-blockers could be evaluated for increasing cardiomyocyte division in patients with ToF/PS and other types of CHD.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31597755 PMCID: PMC8132604 DOI: 10.1126/scitranslmed.aaw6419
Source DB: PubMed Journal: Sci Transl Med ISSN: 1946-6234 Impact factor: 17.956